Whole-blood transcriptomic profiling highlights rituximab response in rheumatoid arthritis

ABSTRACT: Objective: We performed whole-blood transcriptomic profiling for patients with rheumatoid arthritis (RA) who received rituximab (RTX). We aimed to identify a molecular signature that could predict the clinical response to RTX and transcriptomic changes after RTX therapy. Methods: We performed a microarray assay of the whole human genome with RNA from a peripheral blood sample taken before the first RTX cycle from 68 patients included in the SMART study (24 EULAR non-responders and 44 responders at week 24). The transcriptomic profile was also assessed 24 weeks after the first RTX administration

ORGANISM(S): Homo sapiens

SUBMITTER: Florent Dumont 

PROVIDER: E-GEOD-54629 | biostudies-arrayexpress |

REPOSITORIES: biostudies-arrayexpress